ASCO 2023 | Optimal therapy sequencing in kidney cancer

Toni Choueiri, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the most efficacious therapy sequence for the management of kidney cancer as well as some novel therapeutic targets of interest that may impact contemporary treatment strategies. Dr Choueiri outlines the use of PD-(L) inhibitors for first line therapy, followed by tyrosine kinase inhibitors (TKIs) as a second line intervention. The use of HIF-2 inhibitors and CAR-T-cell therapy are also of interest in the management of kidney cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.